Consultants Forum Advertise
Subscribe
Close

  • Free for qualified executives and consultants to industry

  • Receive quarterly issues of Area Development Magazine and special market report and directory issues

Subscribe Now
Renew

Area Development - Site Selection, Facility Planning and Workforce Development

Alnylam Pharmaceuticals Expands Norton, Massachusetts, Operations

12/29/2025
RNAi therapeutics company Alnylam Pharmaceuticals, Inc. plans to expand its operations in Norton, Massachusetts.

The $250 million project will increase the company’s capabilities to produce both clinical and commercial supply of siRNA oligonucleotide drug substance at the company’s existing manufacturing facility.

"At this pivotal time with our expanding pipeline of RNAi therapeutics, Alnylam is accelerating development of siRNA manufacturing and changing what’s possible in a single facility,” said Yvonne Greenstreet, M.D., MBA, Chief Executive Officer of Alnylam. “This advance will be a critical enabler in the scaling of our pipeline to include potential treatments for diseases such as hypertension, type 2 diabetes, and obesity.”

Alnylam Pharmaceuticals develops RNA interference (RNAi) therapeutics. The company’s approved drugs include ONPATTRO, GIVLAARI, AMVUTTRA, and OXLUMO, and a pipeline for conditions like cardiovascular and neurological disorders.

“Alnylam represents the world-class health care innovation Massachusetts is known for. Alnylam has been a leader in life sciences in our state for over two decades,” noted Governor Maura Healey. “Their scientific breakthroughs in siRNA manufacturing have transformed care by providing RNAi therapeutics to people who need it most, while creating thousands of jobs across our state. We're excited to support their growth through the expansion of a manufacturing facility in Southeastern Mass., and we're grateful for their continued investment in Massachusetts.”

“Alnylam’s continued investment in Massachusetts underscores the Commonwealth’s role as a global leader in biomanufacturing,” added Dr. Kirk Taylor, President and CEO of the Massachusetts Life Sciences Center (MLSC). “This expansion will bring high-quality jobs to this area and ensure patients worldwide have the opportunity to benefit from medicines made right here in Massachusetts. We look forward to deepening our partnership as we work together to advance the thriving life sciences ecosystem here in the Commonwealth.”

Exclusive Research